CO4970824A1 - Metodo para reducir las ansias de consumo en mamiferos - Google Patents

Metodo para reducir las ansias de consumo en mamiferos

Info

Publication number
CO4970824A1
CO4970824A1 CO98062495A CO98062495A CO4970824A1 CO 4970824 A1 CO4970824 A1 CO 4970824A1 CO 98062495 A CO98062495 A CO 98062495A CO 98062495 A CO98062495 A CO 98062495A CO 4970824 A1 CO4970824 A1 CO 4970824A1
Authority
CO
Colombia
Prior art keywords
anxies
mammals
consumption
reduce
mammal
Prior art date
Application number
CO98062495A
Other languages
English (en)
Inventor
Vicki Coffin
Paul W Glue
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO4970824A1 publication Critical patent/CO4970824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen un método para reducir en un mamífero las ansiasde consumo de alimentos o de una sustancia adictiva. El método consiste en administrar al mamífero una cantidad efectiva de un antagonista de D1 /D5 o un agonista parcial de D1 /D5 solo o en combinación con otros compuestos para el SNC especificados.
CO98062495A 1997-10-28 1998-10-26 Metodo para reducir las ansias de consumo en mamiferos CO4970824A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28

Publications (1)

Publication Number Publication Date
CO4970824A1 true CO4970824A1 (es) 2000-11-07

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98062495A CO4970824A1 (es) 1997-10-28 1998-10-26 Metodo para reducir las ansias de consumo en mamiferos

Country Status (16)

Country Link
EP (1) EP1043980A2 (es)
JP (1) JP2001520989A (es)
KR (1) KR20010031470A (es)
CN (1) CN1283116A (es)
AR (1) AR015984A1 (es)
AU (1) AU1110099A (es)
BR (1) BR9814830A (es)
CA (1) CA2308453A1 (es)
CO (1) CO4970824A1 (es)
HU (1) HUP0100115A2 (es)
IL (1) IL135659A0 (es)
NO (1) NO20002149L (es)
PE (1) PE122299A1 (es)
SK (1) SK5812000A3 (es)
WO (1) WO1999021540A2 (es)
ZA (1) ZA989786B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
CA2463987C (en) 2001-11-05 2011-03-08 Seth Lederman Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
EP3170499A1 (en) 2010-09-01 2017-05-24 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
KR20150029713A (ko) 2012-07-12 2015-03-18 사이아돈 파마슈티컬스, 인코포레이티드 투렛 증후군의 치료를 위한 융합된 벤즈아제핀
US9949983B2 (en) 2013-10-18 2018-04-24 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of stuttering
CN110327350B (zh) * 2019-07-11 2021-02-23 温州医科大学 多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
CN110833621A (zh) * 2019-12-06 2020-02-25 中国医科大学 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) * 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Also Published As

Publication number Publication date
IL135659A0 (en) 2001-05-20
HUP0100115A2 (hu) 2001-06-28
KR20010031470A (ko) 2001-04-16
WO1999021540B1 (en) 1999-10-28
BR9814830A (pt) 2000-10-03
PE122299A1 (es) 1999-12-04
WO1999021540A2 (en) 1999-05-06
EP1043980A2 (en) 2000-10-18
AR015984A1 (es) 2001-05-30
CA2308453A1 (en) 1999-05-06
WO1999021540A3 (en) 1999-09-02
SK5812000A3 (en) 2000-12-11
JP2001520989A (ja) 2001-11-06
NO20002149L (no) 2000-06-26
AU1110099A (en) 1999-05-17
NO20002149D0 (no) 2000-04-27
ZA989786B (en) 1999-04-28
CN1283116A (zh) 2001-02-07

Similar Documents

Publication Publication Date Title
CO4970824A1 (es) Metodo para reducir las ansias de consumo en mamiferos
UA41316C2 (uk) Трициклічні похідні піролу і фармацевтичний препарат
FR2625266B1 (fr) Demarreur coaxial
DE3872666D1 (de) Schmiermittelzusammensetzung zur verminderung des brennstoffverbrauchs.
EE03975B1 (et) Keratinotsüüdi kasvufaktori analoogid
ATE234625T1 (de) Glp-1 zusammensetzungen mit verlängerter wirkdauer
ES2118393T3 (es) Posavaso quimiluminiscente.
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
DK103788D0 (da) Smoeremiddelkomposition til krumtaphuse
DE3562267D1 (en) Phenanthridinium ester as a labelling compound in luminometric immunoassay
SV2002000244A (es) Metodos y compuestos para inhibir mrp1 ref.x-13353
DE68901910D1 (de) Zweitaktmaschinen-schmieroelzusammensetzung.
NO993626L (no) Blanding omfattende en oljeoppløselig avleiringsinhibitor
DE3872333D1 (de) Doxazosin als antiatherosklerotikum.
ATE297402T1 (de) Phospholipide mit ungesattigten alkyl- und acylketten
ES530943A0 (es) Procedimiento para determinar el contenido de una varilla combustible.
EA199800200A1 (ru) Ингибиторы пролилэндопептидазы
IS4673A (is) Ljósvirk fenýl pýrimidín afleiða sem kvalastillandi miðill
IL88366A0 (en) Tert-butylphenyl compounds useful as anti-inflammatory agents
ECSP982714A (es) Metodo para reducir las ansias de consumo en mamiferos (caso cn0792k)
DE69227337D1 (de) Copolyestercarbonat-Zusammensetzung
DK0898557T3 (da) Vandopløselige trisubstituierede 1,2-dioxetan, der har forbedret lagringsstabilitet, syntetiske processer og mellemprodukter
DE3873562D1 (de) Beta-alkylmelatonine.
EA200000069A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
ATE34661T1 (de) Verbindungen zur verminderung des lipidspiegels.